<DOC>
	<DOCNO>NCT01948180</DOCNO>
	<brief_summary>To investigate efficacy autologous EBV-specific T-cells treatment patient aggressive EBV positive extranodal NK/T-cell lymphoma</brief_summary>
	<brief_title>Cellular Immunotherapy Treatment Antigen-Directed EBV Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<criteria>FOR SCREENING PHASE : 1 . Diagnosis extranodal NK/T lymphoma , per WHO classification , 4th ed. , must include EBV tumor positivity , measure either EBV encode RNA ( EBER ) LMP1 immunostaining . 2. ) Active Disease ( 1 ) Clinically suspect documented relapse/progression , first second relapse follow least one cycle asparaginasebased chemotherapy regimen OR ( 2 ) Initial disease first second relapse unable tolerate one full cycle asparaginasebased chemotherapy regimen OR b ) Highrisk disease ( stage III/IV , KPI group 34 IPI intermediatehigh ) prior second CR regardless previous chemotherapy . 3 . Male female ≥ 18 year age . 4 . Weigh ≥ 35 kg . 5 . ECOG performance score 02 , inclusively . 6 . Negative βhCG test woman childbearing potential . 7 . Able understand comply requirement study provide write informed consent . 1 . CNS lymphoma . 2 . NK cell leukemia . 3 . Hemophagocytic lymphohistiocytosis . 4 . Positive HIV , hepatitis B , hepatitis C , syphilis human T Cell leukemia virus ( HTLV ) . 5 . Use systemic corticosteroid &gt; 0.5 mg/kg/day within 10 day prior obtain 200 mL whole blood start material . 6 . Patient pregnant lactating . 7 . Active second malignancy . 8 . Any prior allogeneic hematopoietic stem cell solid organ transplant . 9 . Asparaginase refractory disease , define one following : 1 . Progression time initial asparaginase base chemotherapy 3 month end initial asparaginase base chemotherapy , OR 2 . Failure achieve least PR initial asparaginase base chemotherapy . 10 . Absolute lymphocyte count ( ALC ) &lt; 400/µL . 11 . Any previous autologous EBV specific T cell treatment . 12 . Systemic fungal , bacterial , viral infection control . 13 . Third great relapse . FOR TREATMENT PHASE : 1 . Documented relapse progression follow least one prior cycle asparaginasecontaining chemotherapy regimen . 2 . Active disease base one follow present baseline study visit within two week prior baseline study visit : 1 . Imaging ( may use local imaging ) 2 . Clinical sign ( ) include skin lesion consistent lymphoma , organ dysfunction organomegaly attributable cause ; clinical sign ( ) 3 . Detectable blood plasma ENV DNA ( may use local laboratory ) 3 . Completed recent course chemotherapy least 2 week prior first study drug dose . 4 . Recovery acute hematological , hepatic renal chemotherapyrelated toxicity define ≤ Grade 1 accord NCI CTCAE v4.0 . 5 . Life expectancy ≥ 8 week . 1 . Use investigational agent within prior 4 week . 2 . Radiotherapy within prior 3 week . 3 . Major surgery within prior 2 week . 4 . Systemic corticosteroid within 24 hour prior study drug administration . 5 . Evidence hepatic dysfunction base serum total bilirubin &gt; 3 time upper limit normal ( ULN ) , ALT &gt; 5 time ULN AST &gt; 5 time ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>NKTCL</keyword>
</DOC>